{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T04:24:56Z","timestamp":1745468696653,"version":"3.40.4"},"reference-count":12,"publisher":"S. Karger AG","issue":"1","license":[{"start":{"date-parts":[[2024,9,9]],"date-time":"2024-09-09T00:00:00Z","timestamp":1725840000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2024,9,9]],"date-time":"2024-09-09T00:00:00Z","timestamp":1725840000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Case Rep Oncol"],"abstract":"<jats:p>Introduction: In recent years, trastuzumab and pertuzumab have been used in treatment protocols for patients with HER2-positive colorectal cancer. Although severe thrombocytopenia is an uncommon side effect of anti-HER2 antibody therapy, we present the first patient with HER2-positive metastatic rectal cancer who developed significant thrombocytopenia after trastuzumab and pertuzumab administration. Case Presentation: The condition was identified as drug-induced immune thrombocytopenia associated with trastuzumab and pertuzumab. Despite the discontinuation of anti-HER2 treatment and administration of corticosteroids, and in addition to frequent platelet transfusions, a low platelet count persisted. Consequently, we determined that the patient presented with a condition similar to immune thrombocytopenic purpura (ITP) and selected a treatment approach consisting of eltrombopag, a thrombopoietin receptor agonist. Subsequently, the patient\u2019s platelet count did not decrease further but rather improved. Conclusion: Although uncommon, anti-HER2 antibodies can cause severe thrombocytopenia. Furthermore, if thrombocytopenia persists after treatment discontinuation and the administration of corticosteroids, exploring treatment options aligned with managing ITP is essential. <\/jats:p>","DOI":"10.1159\/000540980","type":"journal-article","created":{"date-parts":[[2024,9,9]],"date-time":"2024-09-09T16:00:53Z","timestamp":1725897653000},"page":"1001-1007","source":"Crossref","is-referenced-by-count":0,"title":["Severe Thrombocytopenia from Trastuzumab and Pertuzumab Combination Therapy in a Patient with HER2-Positive Metastatic Rectal Cancer"],"prefix":"10.1159","volume":"17","author":[{"given":"Dai","family":"Okemoto","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshifumi","family":"Yamaguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariko","family":"Yamaguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toru","family":"Kadono","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroki","family":"Yukami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elham","family":"Fakhrejahani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroki","family":"Nishikawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"127","published-online":{"date-parts":[[2024,9,9]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3390\/genes15070903"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13071664"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2020.103119"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01553-w"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30904-5"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1177\/030089161309900122"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1111\/jcpt.13406"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.21748"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1186\/1756-0500-6-400"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1007\/s13691-021-00520-z"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2019000812"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.2169\/naika.109.2393"}],"container-title":["Case Reports in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/karger.com\/cro\/article-pdf\/17\/1\/1001\/4276083\/000540980.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/karger.com\/cro\/article-pdf\/17\/1\/1001\/4276083\/000540980.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T15:36:38Z","timestamp":1745422598000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000540980"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,9]]},"references-count":12,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,6,18]]}},"URL":"https:\/\/doi.org\/10.1159\/000540980","archive":["Portico"],"relation":{"is-supplemented-by":[{"id-type":"doi","id":"10.6084\/m9.figshare.26786518","asserted-by":"subject"}]},"ISSN":["1662-6575"],"issn-type":[{"type":"electronic","value":"1662-6575"}],"subject":[],"published":{"date-parts":[[2024,9,9]]}}}